Announced details
Anticancer drug, advanced solid tumors, platinum-resistant ovarian cancer, anal squamous cell carcinoma, and colorectal cancer with FBXW7 mutations
Disease control rate of 48.2%, 5 partial responses, 22 cases of stable disease, an 88% reduction in CA-125, a half-life of 24 to 28 hours, and a volume of distribution of 2.00 to 2.67 L
61 patients with advanced solid tumors enrolled in phase 1 (as of April 2026), of whom 56 were evaluable for efficacy
Sumitomo Pharma America, Inc., Sumitomo Pharma's US subsidiary, presented clinical data at ASCO 2026.
The American Society of Clinical Oncology. Its 2026 Annual Meeting will be held in Chicago, US, from 29 May to 2 June 2026.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Clinical data presented at the 2026 ASCO Annual Meeting
| Item | Details |
|---|---|
| Names of Products / Services Covered | SMP-3124LP (novel liposomal CHK1 inhibitor, injectable formulation) |
| Counterparty | American Society of Clinical Oncology (ASCO) |
| Counterparty overview | The American Society of Clinical Oncology. Its 2026 Annual Meeting will be held in Chicago, US, from 29 May to 2 June 2026. |
| Relationship with the Company | Sumitomo Pharma America, Inc., Sumitomo Pharma's US subsidiary, presented clinical data at ASCO 2026. |
| Applicable area | Anticancer drug, advanced solid tumors, platinum-resistant ovarian cancer, anal squamous cell carcinoma, and colorectal cancer with FBXW7 mutations |
| Quantitative Effects | Disease control rate of 48.2%, 5 partial responses, 22 cases of stable disease, an 88% reduction in CA-125, a half-life of 24 to 28 hours, and a volume of distribution of 2.00 to 2.67 L |
| Usage history | 61 patients with advanced solid tumors enrolled in phase 1 (as of April 2026), of whom 56 were evaluable for efficacy |
| Source | Clinical data presented at the 2026 ASCO Annual Meeting |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide an update on the clinical development of SMP-3124LP and the presentation of its first clinical data at ASCO 2026. The Company states that formulating the drug as liposomal nanoparticles may expand its therapeutic window and optimize drug delivery to tumors while limiting exposure to normal tissue.